Objective: Eicosapentaenoic acid (EPA) has recently garnered strong attention given the success of the REDUCE-IT trial, which overturned previous conclusions on EPA and led to its FDA approval for lowering cardiovascular disease risk. Therefore, there is a need to study EPA for cardiometabolic risk factors. Here we focused on EPA's preventative role on hyperglycemia and hyperinsulinemia.
Introduction
Circulating levels of eicosapentaenoic acid (EPA, 20:5n-3) are generally low in the western population [1] . Therefore, increased intake of EPA and other n-3 polyunsaturated fatty acids (PUFA) is hypothesized to ameliorate a range of risk factors that contribute toward cardiometabolic diseases [2] . Notably, EPA has garnered tremendous attention as the recent REDUCE-IT trial showed EPA ethyl esters (Vascepa ® ) substantially reduced the risk of cardiovascular disease in statin-treated patients with elevated triglycerides [3] . As a consequence, the FDA approved EPA ethyl esters for cardiovascular disease risk reduction in select clinical populations. This overturned the dogma on n-3 PUFAs as having no efficacy for lowering the risk of cardiovascular diseases [4] .
The effects of n-3 PUFAs on insulin sensitivity and glucose tolerance remain strongly debated. Several randomized clinical trials have failed to establish the benefits of increased n-3 PUFA intake for treating subjects with insulin resistance, which may be due to a range of factors including poor controls, a focus on treatment rather than prevention, and often a neglect for a diversified human genetic makeup [2, 5, 6] . Furthermore, a unifying mechanism by which n-3 PUFAs such as EPA prevent insulin resistance remains unclear as many studies have relied on heterogenous mixtures of n-3 PUFAs despite evidence that EPA and its long chain counterpart docosahexaenoic acid (DHA) are not structurally or functionally identical [7, 8] . To further complicate matters, many preclinical studies rely on levels of n-3 PUFAs that are not easily achievable in humans [2, 9, 10] . Finally, very little is known about the therapeutic potential of EPAderived metabolites, which represent the next generation of n-3 PUFA research. Thus, the overarching goal of this study was to address these limitations and to determine the underlying mechanism of action.
We first studied if pure EPA ethyl esters, modeling human pharmacological intake, prevent obesity-induced metabolic impairments using C57BL/6J mice. Supporting analyses on the association between fasting glucose levels and dietary intake of PUFAs was conducted using data from the National Health and Nutrition Examination Survey (NHANES) [11] . We then conducted mass spectrometry based metabolomic and lipidomic analyses to identify targets of EPA ethyl esters, which led to the study of EPAderived resolvin E1 (RvE1). RvE1 belongs to a family of PUFA-derived endogenous metabolites known as specialized pro-resolving mediators (SPM) that are potent immunoresolvants [12] [13] [14] [15] [16] [17] . We specifically investigated if exogenous treatment of RvE1 could reverse hyperinsulinemia and hyperglycemia through the G-protein coupled receptor ERV1/ChemR23. Given that RvE1 is an immunoresolvant, immune profiling experiments using flow cytometry addressed if RvE1 mitigates hyperglycemia via an improvement in adipose tissue inflammation in obesity. Furthermore, we determined if the metabolic effects of RvE1 were dependent on the host genome, which is critical to investigate as humans are genetically heterogenous. To do so, we employed diversity outbred (DO) mice, which are a unique mouse population that model human genetic diversity [18] . In parallel, we conducted supporting SNP analyses by mining the Ensembl database to identify genetic variation of EPA and RvE1 metabolizing genes in humans.
Materials and Methods

Animal models, diets, and RvE1 administration. All murine experiments adhered to
IACUC guidelines established by The University of North Carolina at Chapel Hill and East
Carolina University for euthanasia and humane treatment in addition to the NIH Guide for the Care and Use of Laboratory Animals. Euthanasia relied on CO2 inhalation followed by cervical dislocation. C57BL/6J male mice of 5-6 weeks of age were fed lean control (10% kcal from lard, Envigo TD.160407) or high fat (60% kcal from lard, Envigo TD.06414) diet in the absence or presence of EPA (Cayman, >93%) ethyl esters (Envigo TD.160232) for 15 weeks. EPA in the high fat diet accounted for 2% of total energy. The schematic illustrating the generation of the ERV1/ChemR23 mutant allele by CRISPR/Cas9-mediated genome editing is provided in the Supplemental Materials, as described below. These mice and wild type littermate controls were also fed diets from Envigo.
For select studies, C57BL/6J male mice were purchased obese from Jackson at 18 weeks of age. They were acclimatized by feeding lean (10% lard, D12450B) or high fat (60% lard, D12492) diets (Research Diets) for an additional 2-3 weeks prior to conducting experiments. DO male mice (Jackson) from generation 33 were obtained at 4 weeks of age and acclimated for 2 weeks. The DO population is derived from 144
Collaborative Cross lines obtained from Oak Ridge National Laboratory at generations F4-F12 of inbreeding [18] .
Body mass and insulin/glucose measurements. Metabolic studies including Echo-
Magnetic Resonance Imaging (MRI) experiments were conducted as previously described [19] . Briefly, mice were fasted for 5 hours prior to the establishment of baseline glucose values with a glucometer. For the glucose tolerance test, 2.5g of dextrose (Sigma-Aldrich) per kg lean mass was administered intraperitoneally.
2.3 Studies with diversity outbred (DO) mice. Since every DO mouse is genetically unique, each mouse served as its own control. Baseline fasting insulin/glucose measurements were recorded once each DO mouse achieved ~14 grams of fat mass as measured by Echo-MRI. The mice were then allowed one week to recover and subsequently i.p. injected for 4 consecutive days with 300 ng RvE1 per day [20] . Fasting glucose and fasting insulin were again measured after RvE1 administration.
2.4
Untargeted mass spectrometry-based metabolomics. Adipose tissue and liver were homogenized using a bead homogenizer and prepared for metabolomics using previously described methods [21] . Samples were analyzed using liquid chromatography mass spectrometry (LC/MS) and raw data were extracted and processed using Agilent Technologies Mass Hunter Profinder Version B.08.00 (Profinder) software in combination with Agilent Technologies Mass Profiler Professional Version 14 (MPP) as previously described [21] [22] [23] . An in-house database containing METLIN, Lipid Maps, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Human Metabolomics Database (HMDB) was used to annotate metabolites based on exact mass, isotope ratios, and isotopic distribution with a mass error cutoff of 10 ppm. This corresponds to annotation at Metabolomics Standards Initiative (MSI) level 3 [24] .
To visualize clustering between the dietary groups we ran a principal component analysis (PCA) using all metabolites. We then determined statistically significant metabolites between obese mice and obese mice supplemented with EPA. One of the samples from the high fat diet (HF_105) was an outlier from all the other samples and was excluded from analyses. We then calculated fold changes (EPA/high fat). Next, using the validated significant metabolites with Log2 fold changes ±1.5 we standardized the abundances of the metabolites by assigning a Z-score for each sample based on the distribution of the given metabolite. We utilized the Z-scores to generate heatmaps annotated with the classification of each metabolite.
2.5
Targeted mass spectrometry-based metabololipidomics. Analyses of PUFA-derived metabolites of visceral white adipose tissue, liver, and heart was conducted as previously described [25] . Lipid mediators were extracted using Strata-X 33-μm 30 mg/1 ml SPE columns (Phenomenex, Torrance, CA). Quantitation of lipid mediators was performed using two-dimensional reverse phase HPLC tandem mass spectrometry (liquid chromatography-tandem mass spectrometry). All standards and internal standards used for the LC/MS/MS analysis were purchased from Cayman Chemical (Ann Arbor, Michigan, USA). All solvents and extraction solvents were HPLC grade or better.
Flow cytometry analyses of differing immune cell populations in adipose tissue.
Epididymal visceral adipose tissue was mechanically chopped and then digested with collagenase Type 4, DNAse 1, and 0.5% fatty acid free bovine serum albumin in phosphate buffered saline (PBS) for 50 minutes at 37 o C in an incubator-shaker. Next, 0.5M EDTA was added with RPMI media and the cells were passed through a 70-μm cell strainer rinsed with 2% fetal bovine serum (FBS) in PBS. The cells were centrifuged at 1400 RPM for 5 minutes at 4 o C, primary adipocytes were aspirated off from the top layer of the supernatant and the pellet containing the stromal vascular cells (SVC) was then incubated with red blood cell lysis buffer for 1 minute on ice. Two percent FBS-PBS was added to the SVCs and centrifuged at 1400 RPM for 5 minutes at 4 o C and then passed through a 40-μm cell strainer. SVCs were stained with the following fluorophore-tagged antibodies obtained from BioLegend: Zombie Aqua, CD45 (PerCP-Cy5.5), CD11b (FITC), CD19 (APC-Cy7), F4/80 (PE), and MHCII (BV421). The following SVC subsets were analyzed using a BD LSRII flow cytometer: CD45 + CD11b -CD19 + (B cells), 
Results
3.1 EPA limits hyperglycemia, hyperinsulinemia, and improves glucose tolerance of obese male C57BL/6J mice. We first determined if dietary administration of EPA could prevent obesity-induced metabolic impairments of obese male mice. The approach relied on pure ethyl esters of EPA and not mixtures of EPA with DHA that can confound the data. Mice consuming a high fat (HF) diet in the absence or presence of EPA had similar increases in total mass and fat mass compared to lean controls ( Fig. 1A ). Inclusion of EPA in the diet of obese mice prevented the development of obesity-driven glucose intolerance ( Fig. 1B) , as quantified by the area under the curve (Fig. 1C ). Relative to the HF diet, EPA restored the impairment in fasting glucose ( Fig. 1D ) and improved fasting insulin levels (Fig. 1E ). The HOMA-IR score was also lowered with EPA in the diet, relative to the mice consuming the HF diet ( Fig 1F) .
3.2 EPA is associated with improved glucose levels in obese humans in a sex-dependent manner. To translate the murine data, we analyzed the relation between EPA intake and blood glucose levels during an OGTT in obese humans using data from NHANES.
Increased EPA intake was associated with lower glucose levels between the first tertile and the third tertile for obese males ( Fig. 2A ) but not females ( Fig. 2B ). Furthermore, we investigated if there was a relationship between DHA and glucose levels. In obese males The metabolism of EPA relies on some of the same immune responsive and metabolic enzymes used by n-6 PUFAs such as linoleic acid (LA) [26, 27] . Thus, we further mined the NHANES data to determine if there was a relationship between the ratio of LA to EPA on fasting glucose levels. Tertiles of the LA to EPA ratio are plotted for obese men ( Fig. 2E ) and women (Fig. 2F ). The positive association between EPA and glucose levels was diminished and strikingly, at the highest ratio of LA to EPA in men ( Fig. 2E ), but not women ( Fig. 2F ), blood glucose levels were increased relative to the first two tertiles.
3.3 Mice consuming EPA have a distinct metabolome compared to obese mice in the absence of EPA. As the mechanism of action for EPA ethyl esters is likely to be pleiotropic, we conducted metabolic profiling of mice consuming the experimental diets.
PCA plots revealed a clear distinction between the control, HF, and HF + EPA ethyl ester diets for visceral white adipose (Fig. 3A) . EPA ethyl esters were predominately incorporated into triglycerides with some uptake into diglycerides and phosphatidylcholine ( Fig. 3B, 3C ). In the liver, PCA plots also showed a clear distinction between the HF and HF + EPA ethyl ester diets ( Fig. 3D ). EPA ethyl esters appeared to have a broad effect on the liver metabolome ( Fig. 3E, 3F ). EPA acyl chains were likely distributed into triglycerides, phosphatidylcholine, phosphatidylethanolamine, and anandamide ( Fig. 3F ).
Overall, these results showed that EPA ethyl esters are incorporated into several lipid pools, which would then differentially influence metabolic pathways, particularly in the adipose tissue and liver. The full metabolite names, p-values, fold changes, and quantifications are in Supplemental Tables 1 and 2. 3.4 12-HEPE and 18-HEPE levels are lowered with obesity and reversed with EPA. We next conducted targeted metabololipidomic analyses to further study the effects of EPA on the adipose and liver lipidomes. The HF diet and HF diet + EPA modulated several n-3 and n-6 PUFA-derived metabolites in these tissues. The HF diet amplified several white adipose tissue n-6 PUFA derived mediators, many of which are pro-inflammatory, relative to the lean control (Fig. 4A ). These included 11 (12) Inclusion of EPA in the HF diet also amplified some but not all of these metabolites (Fig.   4A ). Markedly, the HF diet lowered the levels of the EPA-derived 18-HEPE, which was reversed with EPA in the diet. 18-HEPE levels were elevated by 5.6 and 32.6-fold relative to the lean and HF diets, respectively (Fig. 4A ). EPA also strongly upregulated the concentration of 12-HEPE in white adipose tissue by ~58-fold.
In the liver, the n-6 PUFA-derived LXA4 and PGE2 were increased with the HF diet relative to the lean control ( Fig. 4B) . Notably, 12-HEPE and 18-HEPE levels were undetectable with the HF diet compared to the control. In contrast, EPA lowered PGE2 and 9-HODE levels relative to the HF diet. EPA dramatically increased the levels of 12-HEPE and 18-HEPE compared to the lean and HF diets (Fig. 4B ). EPA also elevated the levels of 14-HDHA and 17-HDHA relative to the HF diet.
We also analyzed the heart to determine if the effects of EPA were limited to white adipose tissue and liver. In the heart, EPA had some modest effects on the number of n-6 PUFA derived metabolites modified relative to the HF diet (Suppl. Fig. 1 ). However, similar to the adipose tissue and liver, EPA increased the concentration of 12-HEPE and 18-HEPE by up to 11-27 fold relative to the lean and HF diets, respectively (Suppl. Fig.  1 ). Overall, the robust amplification of 18-HEPE levels set the basis for subsequent experiments with RvE1, the downstream and immune responsive bioactive of 18-HEPE.
3.5 RvE1 treatment improves hyperinsulinemia and controls hyperglycemia of inbred mice in a manner that is dependent on the receptor ERV1/ChemR23. Given that EPA strongly upregulated 18-HEPE, we subsequently investigated the effects of RvE1 on fasting insulin and glucose using C57BL/6J mice. Furthermore, we tested the hypothesis that the effects of RvE1 could be mediated by one of its two receptors known as ERV1/ChemR23. Therefore, we generated ERV1/ChemR23 knockout (KO) mice and wild type (WT) littermates to measure the effects of RvE1 on hyperinsulinemia and hyperglycemia. Figure 5A and 5B respectively show the experimental scheme and the ERV1/ChemR23 deletion allele. Body composition did not differ between obese WT and ERV1/Chem23 KO mice administered vehicle control or RvE1 (Fig. 5C ). RvE1 treatment improved fasting glucose levels of WT but not ERV1/ChemR23 KO mice compared to obese mice (Fig. 5D ). We also tested fasting insulin levels in a subset of our WT and KO mice via an ELISA. Fasting insulin levels were improved in response to RvE1 in WT obese mice but not in ERV1/ChemR23 KO obese mice relative to obese mice that received the vehicle control (Fig. 5E ).
We also determined if the RvE1 treatment limits hyperglycemia and hyperinsulinemia using C57BL/6J as a second diet model system (diets from Research Diets) that are prone to obesity and obesity-induced metabolic defects, which were mice obtained obese from Jackson Laboratories. RvE1 treatment of obese mice had no effect on body weight (Fig. 5F ) compared to the mice on a high fat diet. RvE1 restored fasting glucose ( Fig. 5G ) and improved fasting insulin levels relative to obese mice (Fig. 5H ).
Mechanistically, immune cells such as B lymphocytes and macrophages in white
adipose tissue have a central role in regulating glucose metabolism and thereby metabolic homeostasis. Furthermore, previous work shows that resolvin D1 improves glycemic control by targeting the number of M1-and M2-like macrophages in white adipose tissue [13] . Thus, we investigated if RvE1 was preventing the enrichment of key immune cells in visceral white adipose tissue. The flow cytometry gating strategy is depicted in Fig. 6A and fluorescence minus one controls are shown in Suppl. Fig. 2 . For this select study, we only compared mice consuming a HF diet in the absence or presence of RvE1 as significant pooling of lean mice was required. Strikingly, the analyses revealed RvE1 had no effect on the percentage of CD45 + CD11b -CD19 + B cells (Fig. 6B ), CD45 + CD11b + F4/80 + MHCII + macrophages (Fig. 6C ), or CD45 + CD11b + F4/80 + MHCIImacrophages ( Fig. 6D) . Similarly, there was no effect of RvE1 on the number of CD45 + CD11b -CD19 + B cells (Fig. 6E ), CD45 + CD11b + F4/80 + MHCII + macrophages (Fig.   7F ), or CD45 + CD11b + F4/80 + MHCIImacrophages ( Fig. 6G ). We also probed if RvE1 had any impact on select inflammatory and metabolic transcripts. qRT-PCR analysis revealed no effect of RvE1 on the expression of adiponectin, Tnfa, IL10, and GLUT-4 (data not shown).
3.6
Host genetics define the treatment response to RvE1. Humans are metabolically heterogeneous with a diversified genetic makeup therefore, we determined whether host genetic differences lead to variations in the fasting insulin and fasting glucose response to RvE1. For these studies, we used the translational DO mouse model that mimics human genetic diversity and variability [18] . Similar to the human population, administration of a high fat diet led to large variations in body weight gain of DO mice.
Thus, we optimized an experimental design (Fig. 7A) The results with the DO mice led us to further investigate if there is strong genetic variation in RvE1-and EPA-metabolizing genes in humans. We mined the Ensembl database containing the dbSNP archive and 1000 genomes data (Suppl. Table 3 ). We extracted all the CYP450 enzymes that have the capacity to metabolize EPA, further downstream enzymes leading to the production of E-series resolvins (COX2, ALOX5, FLAP, ALOX12/15, LTA4H), and the two RvE1 receptors (ChemR23 and BLT1) [28] [29] [30] .
The analyses show a large range of minor allele frequencies where SNPs for each gene are contained in chromosomes 1, 10, 12-15, 17 and 19 with BLT1 lacking SNPs in chromosome 14 (Fig. 7F) . Genes with lower ranges of minor allele frequencies (MAF) ranging from 0.05 (5%) -0.38 (38%) include BLT1, COX2, CYP2J2, CYP1A1 and
Discussion
There is growing evidence from humans and rodents that obesity impairs the biosynthesis of SPMs and their precursors, which are predominately generated from dietary n-3 PUFAs including EPA [14, 19, 31, 32] . The loss of SPMs contributes toward a range of cardiometabolic complications including chronic inflammation, hepatic steatosis, insulin resistance, susceptibility to infection, and delayed wound healing [13, 15, 25, [32] [33] [34] [35] . Therefore, there is an unmet need to understand how specific dietary n-3 PUFAs through the biosynthesis of their downstream metabolites regulate outcomes in cardiometabolic and inflammatory diseases.
This study advances the field by demonstrating that administration of EPA ethyl esters can prevent hyperinsulinemia and control hyperglycemia through the actions of RvE1 in a host genetic dependent manner. One notable outcome were the data from the NHANES analyses, which underscore the need for preventative precision nutrition studies with EPA. Longitudinal studies with EPA that are focused on prevention, prior to the onset of insulin resistance, are limited. One pilot study demonstrated that administration of n-3
PUFAs to healthy human volunteers prevented insulin resistance induced with a glucocorticoid [36] . The NHANES analyses revealed those subjects with lowest consumption of EPA, but not DHA, had the highest glucose levels in a sex-specific manner. The positive effects of EPA were mitigated when the intake of LA was high, which is common in the western diet. While these data are associative, they point to the importance of discriminating EPA from DHA and accounting for LA levels in clinical studies and trials. LA biosynthesis and metabolism requires some of the same enzymes used for EPA synthesis and metabolism, including the endogenous biosynthesis of downstream metabolites such as RvE1 [26, 27] . Moreover, LA's consumption in the western diet is 14-18 times the amount required to prevent LA deficiency [2, 37] and LA's effects on insulin sensitivity are debated [38] . LA is an essential signaling PUFA for human and animal health but its overconsumption may contribute toward chronic inflammation and metabolic impairments.
The data with EPA ethyl esters challenge previous findings. Earlier studies reported a reduction in fat mass with EPA-containing oils, which we did not observe [39, 40] . The differences in results using EPA ethyl esters compared to previous findings on body weight maybe due to the concentration/purity of EPA, duration, and use of EPA/DHA mixtures. EPA driving an upregulation in the concentration of RvE1's precursor is highly consistent with a recent clinical trial to show that consumption of an n-3 PUFA supplement promoted a strong upregulation of SPMs within 24 hours [41] .
A second major advancement are the data to show that RvE1 could improve hyperinsulinemia and hyperglycemia via ERV1/ChemR23. RvE1 treatment is likely exerting its effects through multiple mechanisms. There is evidence that RvE1 blocks signaling through BLT1, the receptor for the arachidonic acid-derived LTB4 [16] . The proinflammatory mediator LTB4 serves as a chemokine for select immune cell populations that exacerbate glucose intolerance, particularly in white adipose tissue [42] . We did not find evidence that RvE1 is targeting the enrichment of immune cell populations in the adipose tissue as reported for resolvin D1 [13] . The data are consistent with a study to show that protectin DX could improve insulin resistance independent of an effect on adipose tissue inflammation [17] . We did find that RvE1's parent compound EPA lowered some pro-inflammatory n-6 PUFA-derived mediators, which could also influence the longterm inflammatory milieu.
RvE1 activation of ERV1/ChemR23 may be further inhibiting signaling through chemerin, an adipokine that binds ERV1/ChemR23 [43] . At the organ and cellular level, RvE1 can improve inflammation though the targeting of intestinal alkaline phosphatase and specific cell types including neutrophils and through the production of further downstream metabolites such as 18-oxo-RvE1 [32, 35, 44, 45] . The effects of RvE1 are likely to occur simultaneously with other EPA-derived metabolites. Notably, we observed EPA strongly upregulated the concentration of 12-HEPE, which was recently identified to improve glucose metabolism [46] .
There is some ambiguity among studies regarding the effects of RvE1 on hyperglycemia. Overexpression of ERV1/ChemR23 in myeloid cells improved hyperglycemia and hepatic steatosis of male mice [47] . However, RvE1 administration to wild type mice at a dose of 2ng/g body weight twice weekly for four weeks did not improve hyperglycemia [47] . Our studies relied on a dose of RvE1 (300ng/mouse) for four consecutive days, which may explain the positive effects. Overall, our data on RvE1 were in agreement with the literature to show that select DHA-derived SPMs improve insulin resistance [13, 17, 33, 48, 49, 50] . For instance, the DHA-derived SPM protectin DX and resolvin D1 enhances glucose tolerance [13, 17] .
A final advancement from this study is that DO mice, which model human genetic diversity, respond in a divergent manner upon RvE1 administration. The results open a new area of investigation by suggesting that RvE1 is unlikely to have a uniform positive effect in all obese humans. These results underscore the need for precision treatment in the human population. Overall, little is known about the role of host genetics on SPM biology. One study highlights the importance of genetic variation by demonstrating that obese subjects with a C allele in the rs1878022 polymorphism of ERV1/ChemR23 receptor confers protection from adipose tissue inflammation [51] .
The study with DO mice directly informs emerging clinical trials with EPA-derived metabolites on the need to account for the host genome. To exemplify, a recent placebo controlled randomized trial with a 15-hydroxy EPA ethyl ester (Epeleuton) showed an improvement in glycemic control, HbA1c, and inflammation in adults with non-alcoholic fatty liver disease [52] . Therefore, studies such as this one may find more robust effects in future precision clinical trials. To support this conclusion, mining the 1000 genomes and dbSNP databases revealed a large range of minor allele frequencies in the EPA and RvE1-metabolizing genes. Most of the genes analyzed reach minor allele frequencies close to 50%, indicating large population variance in the EPA-RvE1 pathway.
Furthermore, close proximity of the CYP450 enzyme SNPs suggest potential genetic linkage in many of the CYP450 variants that can potentially influence metabolism of EPA and its downstream metabolites. The results provide strong groundwork for future genetics studies that will establish candidate genes regulating the metabolic response to
RvE1. This will allow investigators to establish 'responders' from 'non-responders' to EPA-derived metabolites in humans.
Conclusions
In summary, the results provide strong evidence that the EPA-RvE1 axis has a critical role in controlling insulin and glucose homeostasis, which may be a preventative target for cardiometabolic diseases. The results across model systems highlight the need for future prevention and treatment studies that account for the role of host genetics in the metabolism of RvE1 and other EPA-derived metabolites. 
Figure Legends
